Display options
Cite
Cristina de LC, Del Rosario RM, Carmen Rosa A, et al. On the performance of trimetazidine and vitamin e as pharmacoprotection agents in cyclosporin a-induced toxicity. ISRN Pharmacol. 2013;2013:605640doi: 10.1155/2013/605640.
Cristina, d. e. . L. C., Del Rosario, R. M., Carmen Rosa, A., & Ana Veronica, O. (2013). On the performance of trimetazidine and vitamin e as pharmacoprotection agents in cyclosporin a-induced toxicity. ISRN pharmacology, 2013605640. https://doi.org/10.1155/2013/605640
Cristina, De la Cruz Rodríguez Lilia, et al. "On the performance of trimetazidine and vitamin e as pharmacoprotection agents in cyclosporin a-induced toxicity." ISRN pharmacology vol. 2013 (2013): 605640. doi: https://doi.org/10.1155/2013/605640
Cristina de LC, Del Rosario RM, Carmen Rosa A, Ana Veronica O. On the performance of trimetazidine and vitamin e as pharmacoprotection agents in cyclosporin a-induced toxicity. ISRN Pharmacol. 2013 Apr 11;2013:605640. doi: 10.1155/2013/605640. Print 2013. PMID: 23691353; PMCID: PMC3654278.
Copy Download .nbib Format: NLM
Share it on

ISRN Pharmacol. 2013 Apr 11;2013:605640. doi: 10.1155/2013/605640. Print 2013.

On the performance of trimetazidine and vitamin e as pharmacoprotection agents in cyclosporin a-induced toxicity.

ISRN pharmacology

De la Cruz Rodríguez Lilia Cristina, Rey María Del Rosario, Araujo Carmen Rosa, Oldano Ana Veronica

Affiliations

  1. Clinical Biochemistry III, Instituto de Bioquímica Clínica, Facultad de Bioquímica Química y Farmacia, Universidad Nacional de Tucumán, Balcarce 747, Tucumán, 4000 San Miguel de Tucumán, Argentina.

PMID: 23691353 PMCID: PMC3654278 DOI: 10.1155/2013/605640

Abstract

The immunosuppressant drug cyclosporin A (CyA) has been used in diseases with immunological basis and in transplant patients. Nephrotoxicity and hepatotoxicity are the main adverse effects of this drug. To find a protective drug against those effects we assayed the cardioprotector Trimetazidine (TMZ) and vitamin E, used as nutritional supplements to alleviate oxidative stress. Six groups of eight male Wistar rats each were prepared (groups A-F): A, control; B, vitamin E (10 mg/Kg/day); C, TMZ (20 mg/Kg/day); D, 25 mg/Kg/day CyA; E, CyA and vitamin E (25 mg/Kg/day CyA + 10 mg/Kg/day Vit E); F, TMZ for 20 days (20 mg/kg/day); and then CyA (25 mg/kg/day) and TMZ (20 mg/Kg/day). The experiment lasted 120 days. The exposure of rats to CyA promoted nephrotoxicity and hepatotoxicity with an increase in serum urea, creatinine, and glutamate dehydrogenase (GLDH). Structural and ultrastructural studies of liver and kidney were performed. Group D showed adverse effects induced by CyA since statistically significant differences were found with respect to the control group (A). Vitamin E (E) showed no protective effect. Pretreatment with TMZ (F) attenuated the adverse effects of CyA. We conclude that CyA-induced nephrotoxicity and hepatotoxicity are attenuated by the cytoprotective effect of TMZ. TMZ inhibits the reabsorption and, consequently, the accumulation of CyA in the cell. The antioxidant capacity of vitamin E did not improve the effect of CyA.

References

  1. Gastroenterol Hepatol. 2010 Jan;33(1):54-65 - PubMed
  2. J Appl Toxicol. 2007 Jul-Aug;27(4):310-7 - PubMed
  3. Life Sci. 2003 Nov 14;73(26):3387-97 - PubMed
  4. J Clin Pathol. 1960 Mar;13:156-9 - PubMed
  5. Curr Med Res Opin. 2003;19(7):661-72 - PubMed
  6. Clin Chem. 1961 Dec;7:665-73 - PubMed
  7. Clin Chim Acta. 1976 Jul 15;70(2):F19-29 - PubMed
  8. Eur J Clin Invest. 1994 May;24(5):355-9 - PubMed
  9. Transplant Proc. 1994 Oct;26(5):2916-7 - PubMed
  10. Toxicol Appl Pharmacol. 2009 Sep 15;239(3):241-50 - PubMed
  11. Biochem Pharmacol. 2000 May 1;59(9):1091-100 - PubMed
  12. J Appl Toxicol. 2010 May;30(4):343-53 - PubMed
  13. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):68-73 - PubMed
  14. Transplantation. 2001 Jan 27;71(2):331-4 - PubMed
  15. Nefrologia. 2007;27(5):565-73 - PubMed
  16. Immunopharmacology. 2000 May;47(2-3):119-25 - PubMed
  17. Toxicology. 2003 Jul 15;189(1-2):99-111 - PubMed
  18. Circ Res. 2000 Mar 17;86(5):580-8 - PubMed
  19. Methods Find Exp Clin Pharmacol. 2003 Dec;25(10):803-9 - PubMed
  20. Curr Pharm Des. 2005;11(4):489-509 - PubMed
  21. Hepatol Res. 2008 Apr;38(4):385-92 - PubMed
  22. Histol Histopathol. 2006 Mar;21(3):301-16 - PubMed
  23. Transpl Immunol. 2002 Nov;10(4):255-8 - PubMed
  24. Eur J Pharmacol. 2004 Oct 25;503(1-3):123-8 - PubMed

Publication Types